SEC Form 4 · accession 0001144204-15-028486
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yoseph Shaaltiel
Officer — Executive VP, R&D
Period of report
Mar 23, 2015
Accepted (ET)
May 7, 2015 · 5:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001006281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2,F1 | $1.72 | Mar 23, 2015 | A | 275,000 | A | — | Mar 23, 2025 | Common Stock | 275,000 | 275,000 | D |
Explanation of responses
- F125% of the shares of common stock underlying the stock options shall vest on the first one-year anniversary of the date of grant and the remaining 75% of the shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing on such anniversary. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
- F2Does not include options to purchase 122,162 shares of common stock at an exercise price equal to $0.001 per share that expire on June 30, 2016; options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018; options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; and options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.